Lyrica's DEA Scheduling Will Not Hold Back Sales, Pfizer Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer CEO McKinnell says "the level of scheduling we're anticipating...should not have a significant impact on our opportunity" with Lyrica. Pfizer will work to lift DEA's scheduling for Lyrica, Senior VP Feczko says.
You may also be interested in...
Pfizer’s Lyrica Will Undergo Phase IV Vision, Nerve Impairment Studies
Pfizer also commits to a post-marketing study of pregabalin’s propensity to induce CYP-enzyme metabolism. Lyrica is undergoing controlled substance scheduling by DEA. The European Medicines Agency says that study data suggest pregabalin is not a “prototypic” risk for abuse when compared to diazepam.
Pfizer Lyrica Undergoing Controlled Substance Scheduling At DEA
FDA clears pregabalin for management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia. The Neurontin follow-on compound remains "approvable" for the adjunctive treatment of partial seizures in adults with epilepsy.
Lupus Guidance Suggests Broad Use Of Health-Related Quality Of Life Endpoint
FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.